NASDAQ$ALEC
Alector Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Alector reported financial results for the first quarter ended March 31, 2020.
Alector reported collaboration revenue of $7.2 million and a net loss of $40.0 million for the quarter ended March 31, 2020. The company's cash, cash equivalents, and marketable securities were $548.5 million as of March 31, 2020.
- Continued execution across immuno-neurology platform.
- On track to initiate pivotal Phase 3 trial of AL001 in patients with frontotemporal dementia with a progranulin mutation (FTD-GRN) and a Phase 2 study of AL002 in Alzheimer’s disease patients in 2020.
- Strong cash and investments position of $548.5 million to support execution of clinical, research, and operational goals.
- Alector entered into a regional licensing agreement with Innovent Biologics for the development and commercialization of AL008 in oncology indications in China.
Headline financials
Revenue & EPS history
Alector · Revenue · Quarterly
$7.17M
Revenue by segment
Alector · $7.17M total across 1 segment · Q1 2020
- Collaboration Revenue$7.17M+27.9%100.0%
Forward guidance
Alector remains on track with previously stated guidance to initiate a pivotal Phase 3 study of AL001 in FTD-GRN patients in 2020 and also intends to initiate a Phase 2 study of AL002 in Alzheimer’s disease patients in 2020. The Company believes that its cash and investments as of March 31, 2020 will be sufficient to fund its anticipated operations through 2022.
Tailwinds
- The Company remains on track to advance AL001 into a pivotal Phase 3 study in FTD-GRN patients in 2020.
- Alector expects to present preliminary Phase 2 data of AL001 in FTD-GRN patients at medical meetings in 2020.
- Initial Phase 1a data of AL101 in healthy volunteers are also expected during in 2020.
- Alector has closed enrollment for the Phase 1b study of AL002 and will proceed with initiating a Phase 2 trial in Alzheimer’s disease patients in 2020.
- Alector plans to initiate Phase 1 development for AL014 within the next 12 months.
Headwinds
- As the COVID-19 pandemic continues to evolve, it could impact Alector’s programs in the future.
- Currently, certain clinical trial sites have delayed enrollment of new patients and paused clinical trial visits across clinical development programs.
- Alector is aware that some participants in ongoing trials have not been able to receive scheduled doses on time due to site closures or various state and local shelter-in-place directives.
- The number of patients with available data for presentation may be impacted by the COVID-19 pandemic.
- Alector is actively monitoring the evolving impact of COVID-19 on its operations and clinical trials, with a primary focus on the health and safety of employees, clinical trial participants, and clinical trial site teams.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+1.1%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-5.5%
Avg return
30 days after
52%
15 / 29 earnings
Positive
+32.9%
Q2 2023
Best reaction
-18.4%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.1% | -16.0% | -36.6% | |
| Q4 2025 | +7.1% | -11.7% | -16.3% | |
| Q3 2025 | +4.1% | +8.4% | -2.8% | |
| Q1 2025 | +4.2% | +7.4% | +23.8% | |
| Q4 2024 | -3.5% | -15.4% | -25.0% | |
| Q3 2024 | +12.8% | +21.3% | -56.8% | |
| Q2 2024 | +0.8% | +0.9% | -4.2% | |
| Q1 2024 | -1.9% | +1.7% | -17.7% | |
| Q4 2023 | +7.9% | +14.4% | -7.1% | |
| Q3 2023 | -2.6% | -17.7% | +6.0% | |
| Q2 2023 | +32.9% | +12.4% | -15.6% | |
| Q1 2023 | +13.0% | +20.6% | +8.5% | |
| Q4 2022 | +0.9% | -9.5% | -30.3% | |
| Q3 2022 | -18.4% | +3.1% | +3.1% | |
| Q2 2022 | +16.3% | +12.7% | -6.9% | |
| Q1 2022 | -12.7% | -20.0% | -11.9% | |
| Q4 2021 | +1.9% | -1.3% | -7.8% | |
| Q3 2021 | +2.3% | +4.1% | -20.7% | |
| Q2 2021 | +9.5% | +9.0% | +10.1% | |
| Q1 2021 | -7.8% | -12.4% | +6.1% | |
| Q4 2020 | -4.7% | -10.7% | -14.3% | |
| Q3 2020 | +0.4% | +7.2% | +25.2% | |
| Q2 2020 | -6.9% | -7.4% | -13.5% | |
| Q1 2020 | -5.0% | +0.3% | +3.7% | |
| Q4 2019 | -1.5% | -4.4% | +0.8% | |
| Q3 2019 | -6.1% | -4.2% | +19.5% | |
| Q2 2019 | -1.7% | -18.0% | +9.4% | |
| Q1 2019 | +4.9% | +1.3% | +0.2% | |
| Q4 2018 | -8.6% | -3.5% | +10.8% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro